Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
55 studies found for:    Acid Lipase Disease
Show Display Options
Rank Status Study
21 Recruiting Biomarker for Wolman Disease
Conditions: Wolman Disease;   Acid Lipase Deficiency;   Acid Cholesteryl Ester Hydrolase Deficiency, Wolman Type;   Cholesterol Ester Storage Disease
Intervention:
22 Recruiting Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M
Conditions: Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV);   Neutral Lipid Storage Disease With Myopathy (NLSD-M)
Intervention: Dietary Supplement: CNT-02
23 Completed Oral Sphere: Salivary Markers and Food. A Prospective Study in Children Expressing Oral Disorders
Condition: Oral Disorder
Intervention: Other: Taking of saliva before and after gustatory stimulation
24 Completed Ursodeoxycholic Acid in Bariatric Surgery
Conditions: Non-alcoholic Fatty Liver Disease;   Morbid Obesity
Intervention: Drug: Ursodeoxycholic Acid (UDCA)
25 Unknown  Lovaza Mechanisms of Action
Condition: Moderate Hypertriglyceridemia.
Intervention: Dietary Supplement: Omega 3 fatty acid (Lovaza)
26 Active, not recruiting Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention:
27 Completed Comparison of MAG and Fish Oil Efficacy
Condition: Obesity
Interventions: Dietary Supplement: Fish oil enriched with EPA;   Dietary Supplement: MAG-EPA oil;   Drug: Orlistat
28 Completed Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
Conditions: Obesity;   Nonalcoholic Fatty Liver Disease
Interventions: Dietary Supplement: Resveratrol;   Other: Placebo
29 Completed Substrate Cycling in Energy Metabolism
Conditions: Burns;   Insulin Resistance
Intervention: Drug: fenofibrate
30 Completed Following Lipectomy to Understand Adipose Tissue Re-accumulation
Conditions: Menopause;   Pre-menopause
Intervention: Procedure: Femoral lipectomy
31 Not yet recruiting Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)
Condition: Impaired Glucose Tolerance
Interventions: Drug: Nicotinic acid;   Other: [7,7,8,8-2H]-palmitate;   Other: [U-13C]-palmitate;   Procedure: Biopsy;   Other: liquid meal
32 Unknown  Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: Mycophenolate mofetil;   Drug: cyclosporine
33 Terminated A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Dietary Supplement: Conjugated Linoleic Acid;   Drug: Conjugated Linoleic Acid
34 Unknown  Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
Condition: Breast Cancer
Intervention: Drug: Conjugated Linoleic Acid (CLA)
35 Terminated Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants
Condition: Prevention of Growth Restriction
Interventions: Drug: rhBSSL (recombinant human bile-salt-stimulated lipase);   Drug: Placebo
36 Terminated Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
Condition: Hyperlipoproteinemia Type I
Intervention:
37 Recruiting Thiopurine Induced Pancreatitis in IBD Patients
Conditions: Pancreatitis;   Inflammatory Bowel Diseases
Intervention: Drug: Azathioprine
38 Completed Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
Conditions: Fatty Liver;   Hepatitis
Interventions: Drug: Orlistat (Xenical);   Behavioral: 1400 kcal diet (30% fat)
39 Recruiting Absorption and Safety With Sustained Use of Relizorb Evaluation (ASSURE) Study
Conditions: Exocrine Pancreatic Insufficiency;   Cystic Fibrosis
Interventions: Device: Relizorb;   Other: Impact Peptide 1.5
40 Completed Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome
Condition: Metabolic Syndrome
Interventions: Dietary Supplement: MUFA MOVE! (Monounsaturated fatty enriched diet);   Dietary Supplement: PUFA MOVE! (Polyunsaturated fatty acid enriched diet)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-55) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.